SPP1 mRNA表达与M2巨细胞透和三阴性乳腺癌的不良预后有关
Yu-Chia Chen1, Chia-Ching Chen2, Rong-Fu Chen3,4
1Division of General Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813414, Taiwan.
Current issues in molecular biology
|December 27, 2024
概括
骨质松丁 (SPP1) mRNA是三阴性乳腺癌 (TNBC) 的关键预后生物标志物. 升高的SPP1mRNA与预后不佳相关,并与瘤相关的巨细胞相关,表明有针对性的治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 三重阴性乳腺癌 (TNBC) 是具有不良预后和有限治疗的侵袭性.
- 验证的预测和预后生物标志物对于TNBC患者管理至关重要.
- 识别新的生物标志物可以改善治疗决策和预后准确性.
研究的目的:
- 为了研究SPP1 (骨质素) 作为三阴性乳腺癌中的生物标志物的作用.
- 探索SPP1表达和TNBC预后之间的关联.
- 确定TNBC中与SPP1相关的潜在治疗点.
主要方法:
- 分析来自TNBC和正常组织的RNA-seq数据.
- 基因组丰富分析 (GSEA) 用于识别活性通路.
- 在公共数据集中检查SPP1mRNA表达 (Kaplan-Meier绘图器,TCGA).
- 免疫组织化学评估SPP1蛋白表达在TNBC组织微阵列队列.
- 在SPP1表达和瘤相关巨细胞 (TAMs) 之间的相关性分析.
主要成果:
- 收费类受体信号通路基因在TNBC组织中被上调.
- 在TNBC中,SPP1mRNA表达升高,并与预后不佳相关.
- 在TNBC组织中证实了SPP1蛋白水平,但没有显著影响生存率.
- 在TNBC中,SPP1mRNA表达与M2亚型瘤相关的巨细胞有很强的相关性.
结论:
- SPP1mRNA是三阴性乳腺癌的重要预后指标.
- SPP1 mRNA与TAMs的关联表明它在瘤微环境中的作用.
- 聚焦于Toll-like受体信号通路的向疗法可能对TNBC患者具有升高的SPP1.1有益.
更多相关视频
相关概念视频
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
MicroRNAs
2.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
2.9K


